The safety of incretin-based therapies--review of the scientific evidence.
about
Long-term drug treatment for obesity: a systematic and clinical reviewRegulation of glucose homeostasis by GLP-1General aspects of muscle glucose uptakeExenatide once weekly: opportunities in the primary care setting.Novel GLP-1 Analog Supaglutide Reduces HFD-Induced Obesity Associated with Increased Ucp-1 in White Adipose Tissue in Mice.Potential roles of glucagon-like peptide-1-based therapies in treating non-alcoholic fatty liver disease.Divergent effects of liraglutide, exendin-4, and sitagliptin on beta-cell mass and indicators of pancreatitis in a mouse model of hyperglycaemiaSaxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular dataAmbulatory treatment of type 2 diabetes in the U.S., 1997-2012.Sitagliptin-induced pancreatitis - a longer road than expectedIncretin mimetics as pharmacologic tools to elucidate and as a new drug strategy to treat traumatic brain injuryDipeptidyl-peptidase-4 inhibitors and pancreatic cancer: a cohort study.Comparison of efficacy between incretin-based therapies for type 2 diabetes mellitusChronic continuous exenatide infusion does not cause pancreatic inflammation and ductal hyperplasia in non-human primates.The dipeptidyl peptidase IV inhibitors vildagliptin and K-579 inhibit a phospholipase C: a case of promiscuous scaffolds in proteins.Incretins and amylin: neuroendocrine communication between the gut, pancreas, and brain in control of food intake and blood glucose.Incretin therapy--present and future.Optimizing the Care of Patients With Type 2 Diabetes Using Incretin-Based Therapy: Focus on GLP-1 Receptor Agonists.Update on Safety Issues Related to Antihyperglycemic TherapyDiabetes and thyroid cancer risk: literature review.Effects of exenatide on measures of diabetic neuropathy in subjects with type 2 diabetes: results from an 18-month proof-of-concept open-label randomized studyPotential use of exenatide for the treatment of obesity.Exenatide therapy and the risk of pancreatitis and pancreatic cancer in a privately insured population.Multidisciplinary pharmacotherapeutic options for nonalcoholic Fatty liver disease.Cardiovascular biology of the incretin system.Dipeptidyl peptidase IV inhibition does not adversely affect immune or virological status in HIV infected men and women: a pilot safety study.Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis.What the future holds for gliptins.Interpreting adverse signals in diabetes drug development programs.Cardiac implications of hypoglycaemia in patients with diabetes - a systematic reviewGlucagon-Like Peptide-1 Receptor Agonists for Type 2 Diabetes: A Clinical Update of Safety and Efficacy.Glucagon-like Peptide 1 Drugs as Second-line Therapy for Type 2 Diabetes.Pathogenesis and management of postprandial hyperglycemia: role of incretin-based therapies.Intraduodenal milk protein concentrate augments the glycemic and food intake suppressive effects of DPP-IV inhibition.Insulin plus incretin: A glucose-lowering strategy for type 2-diabetes.The treatment of type 2 diabetes.Incorporating incretin-based therapies into clinical practice for patients with type 2 diabetes.Novel GLP-1 receptor agonists for diabetes.GLP-1 based therapies: differential effects on fasting and postprandial glucose.Alogliptin benzoate for the treatment of type 2 diabetes.
P2860
Q22253010-B1B35EC9-B9AF-4D1D-852B-500A02802C4EQ24563430-88110FBE-7643-411D-9826-106C9D811525Q26991925-2F785BBC-9A1E-4A00-BE99-E126409A0699Q30431639-5E1E96E5-895B-4BA6-80FB-F01FEE51E25FQ33679277-9A9B7C48-2DB6-4898-B7B9-440F960C8C58Q33970970-339AF2AE-B3E5-49FA-B1B8-B2A51C8913F3Q34041974-41778ED1-BA50-4B8C-8371-700E55A3666DQ34128612-EC87DF41-178E-4B24-A5DF-CC24E21AC3B6Q34259412-0B1B8DEB-D82B-4E47-B054-98AF7C175AFEQ34286707-FEB1CAB1-8E87-4111-9E0E-852CE4C05251Q34362412-D645A98E-4695-4E72-AC58-5D64C6E94AD7Q34490448-E9D41AE0-455F-4A53-856B-F488231FA04EQ34496741-CD040C56-53C5-4004-95DA-24312DB2E872Q34780873-49F3FCCF-E4A3-4309-A3AC-33C4E5F4DD71Q35022184-CEFBC7BB-386F-4250-BAA7-CBB2357E57F4Q35690970-6F87770A-6C03-47BD-9E09-E18791B6FE76Q35760283-CD204260-EA42-49E3-8D70-F1C9258C30F8Q35906506-DE723276-309C-4F34-98B3-8C1578C63A57Q35910429-6DF444F1-20A8-493C-8756-F71483F4E2C0Q36063592-EF149203-F868-4446-AA3D-EC4DF16F7A0AQ36307536-459C7EB3-CA42-43E4-9136-6108D2280207Q36391466-AAB2DA9D-86F3-4286-A3E0-6C64B6FF1A1EQ36444054-2BB1D8E7-E627-43C9-9E3F-03DC10BFE49BQ36470320-D519F610-951D-4920-A5E4-5C39C8293755Q36484283-2C76115E-E8D7-4400-89ED-C7DEF04B4D5AQ36589398-1EA81CA0-71A4-4C46-A81B-61528C953EFCQ36649277-DBCB97E8-625C-49C9-B305-4916BD6E4F4CQ36701078-A8BE731D-D2FB-4CA1-ABC4-71322A4CB10BQ36942266-801FC4E6-305B-41AF-8D7B-3E5892366990Q37361386-629CF0CE-1BB7-4EEA-9364-6D006722C066Q37402786-F3196C4B-9189-4C54-B491-DCF77348FF0FQ37427165-430C4155-29F9-4E33-8501-E62244A554A1Q37446672-59BA6044-556F-4C60-8A5D-052C9F6B2136Q37578125-FFD76D3F-D57E-4168-8CFC-775767F094C5Q37598881-8EC3117B-310C-4961-A728-C5D4E453EC61Q37634244-F7913A6F-F6A0-48D6-8C72-9A016605A440Q37653125-02608B21-8072-4A43-A4EF-0C0C21B2B634Q37960149-E3221D52-0F68-498A-85AD-EB7B6670B0D4Q37974712-A80A43C4-FCDC-4D62-9651-9290027EF325Q37980541-6422D32F-984A-4DB8-84CC-5580D7AB2C5D
P2860
The safety of incretin-based therapies--review of the scientific evidence.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on July 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The safety of incretin-based therapies--review of the scientific evidence.
@en
The safety of incretin-based therapies--review of the scientific evidence.
@nl
type
label
The safety of incretin-based therapies--review of the scientific evidence.
@en
The safety of incretin-based therapies--review of the scientific evidence.
@nl
prefLabel
The safety of incretin-based therapies--review of the scientific evidence.
@en
The safety of incretin-based therapies--review of the scientific evidence.
@nl
P50
P356
P1476
The safety of incretin-based therapies--review of the scientific evidence.
@en
P2093
Richard M Bergenstal
P304
P356
10.1210/JC.2011-0599
P407
P577
2011-07-01T00:00:00Z